New hope for Hard-to-Treat lung cancers: targeted immunotherapy combo tested

NCT ID NCT06008093

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tests whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has specific gene mutations (STK11, KEAP1, or KRAS). About 100 participants will receive one of the two treatment combinations. The goal is to see which approach helps people live longer without their cancer growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Beverly Hills, California, 90211, United States
Research Site

La Jolla, California, 92093, United States
Research Site

Los Alamitos, California, 90720, United States
Research Site

Los Angeles, California, 90034, United States
Research Site

Santa Monica, California, 90404, United States
Research Site

Washington D.C., District of Columbia, 20007, United States
Research Site

Fort Lauderdale, Florida, 33308, United States
Research Site

Jupiter, Florida, 33458, United States
Research Site

Ocala, Florida, 34474, United States
Research Site

Orlando, Florida, 32804, United States
Research Site

St. Petersburg, Florida, 33705, United States
Research Site

Atlanta, Georgia, 30318, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Honolulu, Hawaii, 96813, United States
Research Site

Carterville, Illinois, 62918, United States
Research Site

Urbana, Illinois, 61801, United States
Research Site

Bethesda, Maryland, 20817, United States
Research Site

Jamaica Plain, Massachusetts, 02130, United States
Research Site

Saint Paul, Minnesota, 55101, United States
Research Site

Kansas City, Missouri, 64132, United States
Research Site

St Louis, Missouri, 63128, United States
Research Site

Billings, Montana, 59102, United States
Research Site

Grand Island, Nebraska, 68803, United States
Research Site

Lincoln, Nebraska, 68506, United States
Research Site

Albany, New York, 12206, United States
Research Site

East Syracuse, New York, 13057, United States
Research Site

New York, New York, 10032, United States
Research Site

Shirley, New York, 11967, United States
Research Site

Stony Brook, New York, 11790, United States
Research Site

Syracuse, New York, 13210, United States
Research Site

The Bronx, New York, 10461, United States
Research Site

Cleveland, Ohio, 44111, United States
Research Site

Cleveland, Ohio, 44124, United States
Research Site

Cleveland, Ohio, 44195, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Dayton, Ohio, 45459, United States
Research Site

Norman, Oklahoma, 73072, United States
Research Site

Pittsburgh, Pennsylvania, 15212, United States
Research Site

Sioux Falls, South Dakota, 57105, United States
Research Site

Memphis, Tennessee, 38120, United States
Research Site

Dallas, Texas, 75246, United States
Research Site

Denton, Texas, 76210, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Houston, Texas, 77090, United States
Research Site

Kingwood, Texas, 77339, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Richmond, Virginia, 23298, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG